Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA4 | P22748 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517712 | 0.89 | GSTP1 (0.53) | CA12CA4CA9CA1CA2 | |
| SCHEMBL14901574 | 0.85 | CA12 (0.41) | CA12CA4CA9CA1CA2 | |
| SCHEMBL15800551 | 0.84 | CA12 (0.57) | CA12CA4CA9CA1CA2 | |
| SCHEMBL12517384 | 0.84 | CA12 (0.46) | CA12CA4CA9CA1CA2 | |
| SCHEMBL14962824 | 0.82 | SMN1; SMN2 (0.44) | CA12CA4CA9CA1CA2 | |
| SCHEMBL12516483 | 0.82 | CYP19A1 (0.50) | CA12CA4CA9CA1CA2 | |
| SCHEMBL12517711 | 0.80 | HRH3 (0.38) | LTA4HPLA2G2A | |
| SCHEMBL31725799 | 0.79 | CA12 (0.45) | CA12CA4CA9CA1CA2 | |
| SCHEMBL2530176 | 0.78 | KCNA3 (0.50) | LTA4H | |
| SCHEMBL5704167 | 0.78 | CA12 (0.63) | CA12CA4CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | CA12 1486/4885CA4 1520/4885CA9 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.